Video

Dr. Cohen on AEs Associated with BTK Inhibitors in CLL

Jonathon B. Cohen, MD, MS, discusses the adverse effects associated with BTK inhibitors in chronic lymphocytic leukemia.

Jonathon B. Cohen, MD, MS, associate professor, Department of Hematology and Medical Oncology, co-director, Lymphoma Program, chair, Data and Safety Monitoring Committee, Winship Cancer Institute of Emory University, discusses the adverse effects (AEs) associated with BTK inhibitors in chronic lymphocytic leukemia (CLL).

Like any anticancer therapy, BTK inhibitors carry AEs, making it important to remind patients that they must be monitored closely, Cohen says. The most significant AEs associated with BTK inhibitors include a higher incidence of bleeding and an increased risk of atrial fibrillation, Cohen explains.

Other less severe, but problematic, toxicities can include diarrhea, joint aches, headaches, and hypertension, Cohen continues. Individual agents can also lead to an increased risk of specific AEs, such as neutropenia with zanubrutinib (Brukinsa) and headaches with acalabrutinib (Calquence), Cohen says. Patients need to be aware of potential AEs in order to recognize them, Cohen concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center